Premium
MALDI‐MSI for the analysis of a 3D tissue‐engineered psoriatic skin model
Author(s) -
Harvey Amanda,
Cole Laura M.,
Day Rebecca,
Bartlett Maggie,
Warwick John,
Bojar Richard,
Smith David,
Cross Neil,
Clench Malcolm R.
Publication year - 2016
Publication title -
proteomics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.26
H-Index - 167
eISSN - 1615-9861
pISSN - 1615-9853
DOI - 10.1002/pmic.201600036
Subject(s) - psoriasis , dermis , masson's trichrome stain , mass spectrometry imaging , pathology , chemistry , skin equivalent , staining , mass spectrometry , in vitro , medicine , dermatology , biochemistry , chromatography , keratinocyte
MALDI‐MS Imaging is a novel label‐free technique that can be used to visualize the changes in multiple mass responses following treatment. Following treatment with proinflammatory cytokine interleukin‐22 (IL‐22), the epidermal differentiation of Labskin, a living skin equivalent (LSE), successfully modeled psoriasis in vitro. Masson's trichrome staining enabled visualization and quantification of epidermal differentiation between the untreated and IL‐22 treated psoriatic LSEs. Matrix‐assisted laser desorption ionization mass spectrometry imaging was used to observe the spatial location of the psoriatic therapy drug acetretin following 48 h treatments within both psoriatic and normal LSEs. After 24 h, the drug was primarily located in the epidermal regions of both the psoriatic and nonpsoriatic LSE models whereas after 48 h it was detectible in the dermis.